Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study.

Oncologist · 2026 · PMC13006056 · PMID 41761577

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the difference did not reach statistical significance, OS tended to be more favorable in the triplet cohort.

also in 111,027 other papers

showed a trendno p-value reported

Three drugs, triplet therapy showed a trend toward improved survival in patients with poor prognostic factors, suggesting a potential role for risk-adapted regimen selection.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.